Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Viking Therapeutics, Inc. - Common Stock (NQ:VKTX)

28.04 +0.54 (+1.95%)
Streaming Delayed Price Updated: 12:08 PM EDT, May 20, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Viking Therapeutics, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9
...
23 24 Next >
Wall Street Sees Pfizer's Weight-Loss Pill Exit As A Win For 2 Smaller Biotech Firms: Retail Turns Bullish
Investors are now considering the possibility of Pfizer acquiring either of these companies as it looks for external candidates. 
Via Stocktwits
Why Eli Lilly, Novo Nordisk, and Viking Therapeutics Stocks All Popped Today
Pfizer bows, but is not entirely out of the GLP-1 race. 
Via The Motley Fool
What's Going On With Viking Therapeutics, Structure Therapeutics Stock On Monday?
Pfizer ends danuglipron development after liver safety issue, boosting shares of Viking, Eli Lilly, and Novo Nordisk amid obesity drug competition. 
Via Benzinga
Third Harmonic Bio, Apple, Dell And Other Big Stocks Moving Lower In Monday's Pre-Market Session
Via Benzinga
Pfizer Scraps Obesity Pill After Potential Drug-Tied Liver Injury
The company is continuing to test a daily pill that blocks GIPR. 
Via Investor's Business Daily
3 Magnificent Stocks That Could Double or More by 2030
Via The Motley Fool
Will Viking Therapeutics Be a Top Healthcare Stock in 10 Years?
Via The Motley Fool
The Smartest Biotech Stocks to Buy With $50
Via The Motley Fool
Viking Therapeutics, Down 40%, Just Reached a New Milestone. Is the Stock a Buy Now?
Via The Motley Fool
Which Healthcare Stock Is the Best Buy Right Now?
Healthcare stocks provide a combination of upstarts with a high risk, high reward proposition to established firms that can be a defensive maneuver. 
Via MarketBeat
Viking Therapeutics Skids Despite 'Rapid' Enrollment In Obesity Pill Study
The "rapid" enrollment suggests there's still huge interest in the company's approach to obesity treatment. 
Via Investor's Business Daily
Motley Fool 2025 March Market Cap Showdown Championship
Via The Motley Fool
Better Stock to Buy Right Now: Viking Therapeutics vs. Eli Lilly
Via The Motley Fool
MarketBeat Week in Review – 03/17 - 03/21
Stocks gained after the Fed meeting but drifted lower after disappointing guidance from FedEx; next week's inflation data is unlikely to provide needed clarity 
Via MarketBeat
Topics Economy Government World Trade
Exposures Economy Interest Rates Political
10 Health Care Stocks Whale Activity In Today's Session
Via Benzinga
1 Biotech Stock Down 52% That Could Soar by 233%, According to Wall Street
Via The Motley Fool
Down 65% From Its 52-Week High, Is Viking Therapeutics Stock a Bargain Buy?
Via The Motley Fool
Is Novo Nordisk a No-Brainer Buy After It Dropped 40%?
Via The Motley Fool
Is Viking Therapeutics the Next Blockbuster GLP-1 Stock?
Viking Therapeutic may have a GLP-1 blockbuster on their hands with VK2735 as it produces weight loss at 5X the speed of Novo Nordisk's Wegovy GLP-1 drug. 
Via MarketBeat
Why Viking Therapeutics and Roche Holdings Popped Today, but Novo Nordisk Stock Dropped
Ignore the noise in GLP-1 stocks. Find the best value instead. 
Via The Motley Fool
10 Health Care Stocks Whale Activity In Today's Session
Via Benzinga
Viking Therapeutics Just Inked A $150 Million Manufacturing Deal. Here's Why Shares Crumbled.
The company will pay CordenPharma $150 million over three years in a manufacturing deal. 
Via Investor's Business Daily
Is Eli Lilly Stock a Buy?
Via The Motley Fool
The State of Weight Loss Drugs
Via The Motley Fool
BJ's Wholesale Club Posts Better-Than-Expected Earnings, Joins Burlington Stores, Veeva Systems And Other Big Stocks Moving Higher On Thursday
Via Benzinga
AbbVie Enters The Obesity Arena. Why It's Paying Up To $2.23 Billion.
This is the drugmaker's first foray into weight-loss drugs. And it's not focusing on GLP-1. 
Via Investor's Business Daily
MarketBeat Week in Review – 02/24 - 02/28
Stocks tried to stage a weak rally to close the week but the short-term outlook will continue to be dictated by the uncertainty that is creating volatility 
Via MarketBeat
Topics Economy World Trade
Exposures Interest Rates Tariff
1 Biotech Stock to Buy in 2025, and 1 to Avoid
Via The Motley Fool
3 Beaten-Down Biotech Stocks to Buy Before They Soar. Wall Street Is Predicting Jumps of 68% to 250%.
Via The Motley Fool
Viking Therapeutics: Could GLP-1 Maker Be Acquired Pre-Approval?
Viking Therapeutics stock jumped on rumors of a potential acquirer looking to add a GLP-1 treatment to their portfolio and VK2735 appears to rival Zepbound. 
Via MarketBeat
Exposures Product Safety
< Previous 1 2 3 4 5 6 7 8 9
...
23 24 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.